An unnamed biotech company developed a patent-protected CAR-T cell product targeting the Claudin18.2 antigen.
1 report, 1 independent
Updated Jun 22
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
An unnamed biotech company developed a patent-protected CAR-T cell product targeting the Claudin18.2 antigen.